Medipal Holdings Corporation · TSE:7459
Medipal — FY2025 Earnings Presentation
37 slides from Medipal's earnings presentation, May 14, 2026
Slide 1: Financial Results for the Fiscal Year Ended March 31, 2026
May 14, 2026 Financial Results for the Fiscal Year Ended March 31, 2026 Expand, Support, and Connect “Pharmaceuticals, Health, and Beauty” an Orchestra in Support of People's Health The MEDIPAL Group aims to realize a society in which everyone can live with physical and mental well-being and to enha
Slide 2: Conversion of PALTAC into a Wholly Owned Subsidiary: Background and Objectives ①
Regarding the Conversion of PALTAC into a Wholly Owned Subsidiary Background and Objectives ① Structural Changes in the Business Environment • Integrating medical care into daily life by shifting the focus from hospital-centric models to community and home-based support • Facing severe labor shortag
Slide 3: Conversion of PALTAC into a Wholly Owned Subsidiary: Background and Objectives ②
Regarding the Conversion of PALTAC into a Wholly Owned Subsidiary Background and Objectives ② Leveraging management resources across the group Generating anticipated strategic synergies • Strengthening of capacity to provide solutions to business partners and consumers • Building of next-generat
Slide 4: Contents
Contents 1 Financial Results for the FY2025 2 Major Initiatives and Outlook for the FY2026 3 Capital Policy and Shareholder Returns The MEDIPAL Group has three business segments: Regarding the description of the business period ・ Prescription Pharmaceutical Wholesale Business (MEDICEO Business) Fisc
Slide 5: Overview of Financial Results for FY2025
Overview of Financial Results for FY2025 Achieving record-high net sales and ordinary profit Steadily executing growth investments with a decisive medium- to long-term perspective Strengthening and Achieving top-line growth across all business segments, maintaining expansion of core stable group g
Slide 6: FY2025 Consolidated Results [YoY Change]
FY2025 Consolidated Results [YoY Change] Growing gross profit driven by sales expansion Boosting ordinary profit and profit attributable to owners of parent, offsetting higher SG&A expenses from strategic growth investments Increasing adjusted operating profit, highlighting underlying performance by
Slide 7: FY2025 Consolidated Results [Compared to forecast]
FY2025 Consolidated Results [Compared to forecast] Outperforming initial forecasts in both net sales and all profit metrics Amount Difference from Forecast Reasons for the difference from forecast Net Sales ¥3,817.3 billion +¥32.3 billion [+0.9%] - • Gross profit：[¥(2.5) billion] Operating ¥53.1 bil
Slide 8: FY2025 MEDICEO Business [YoY Change]
FY2025 MEDICEO Business [YoY Change] Outpacing market growth in net sales, driven by expanded sales of specialty pharmaceuticals and strong performance in the hospital and pharmacy channels, thereby steadily increasing gross profit Growing adjusted operating profit excluding the impact of expenses r
Slide 9: FY2025 PALTAC Business [YoY Change]
FY2025 PALTAC Business [YoY Change] Achieving net sales growth while seeing a decline in operating profit, primarily driven by rising SG&A and logistics expenditures Driving sales growth through expanded transactions and new product lineups, effectively absorbing rising center fees and retail rebate
Slide 10: FY2025 AGRO&FOOD Business [YoY Change]
FY2025 AGRO＆FOOD Business [YoY Change] Maintaining steady sales performance while gross profit was pressured by rising costs, primarily driven by unfavorable exchange rate fluctuations Accelerating expansion in the companion animal market by integrating Cygni Corporation and leveraging its proven ex
Slide 11: Contents
Contents 1 Financial Results for the FY2025 2 Major Initiatives and Outlook for the FY2026 3 Capital Policy and Shareholder Returns Copyright © 2026 MEDIPAL HOLDINGS CORPORATION, All rights reserved. 11
Slide 12: FY2026 Key Initiatives Aligned with 2027 MEDIPAL Medium-Term Vision
FY2026 Actively driving key initiatives aligned with the growth strategies outlined in the "2027 MEDIPAL Medium-Term Vision" Five growth strategies 1. Expansion of overseas business 2. Expansion of preventive and pre-disease business and AGRO&FOOD business 3. Enhancement of the business with and in
Slide 13: Initiatives for the Growth Strategies: Sustainable Logistics and Digital
MEDICEO Business Initiatives for the Growth Strategies 【Building sustainable logistics business/Enhancement of the business with and in digital】 Realizing a next-generation supply chain by leveraging "the two A's (ALC & AR)" to seamlessly connect customers and manufacturers through data integration
Slide 14: NEXT STAGE: The New Supply Chain the MEDICEO Business Aims For
MEDICEO Business NEXT STAGE; The “New supply chain" that the MEDICEO business aims for Creating a world of seamless medicine delivery and a quantum leap in labor productivity Demand forecasting and Production plan Inventory proposals Inventory and purchasing data Manufacturer MEDIPAL GROUP Customer
Slide 15: Initiatives for the Growth Strategies: Expansion of Overseas Business
MEDICEO Business Initiatives for the Growth Strategies 【Expansion of overseas business】 Accelerating the development of three R&D pipelines targeting ultra-rare diseases, acquired from JCR Pharmaceuticals Co., Ltd., with a focus on rapid launch and early monetization Development progress Non-clinica
Slide 16: Initiatives for the Growth Strategies: Preventive and Pre-disease Business
MEDICEO Business Initiatives for the Growth Strategies 【Expansion of preventive and pre-disease business】 Accelerating the market penetration of PreMedica’s gut microbiome testing service Leveraging microbiome analysis to reduce disease risks and enhance overall performance for our customers Expandi
Slide 17: Integrating Group Resources Across Healthcare and Lifestyle Essentials
PALTAC Business Background to the dissolution of parent-subsidiary listings and future directions Changes in the social environment Changes in the retail industry Strengthening dispensing functions in the drug The arrival of the 100-year life era store sector Expansion of needs for pre-disease
Slide 18: Future developments in line with the long-term vision: Data utilization
PALTAC Business Future developments in line with the long-term vision Data Connecting the entire supply chain with data to create utilization new value ＜The ideal image＞ ＜Knowledge, know-how, and intelligence＞ • Relationship with medical Connecting data scattered throughout institutions/pharmacies,
Slide 19: Future developments in line with the long-term vision: Logistics
PALTAC Business Future developments in line with the long-term vision Logistics The combination of high productivity and expertise creates logistics that are second to none ＜The ideal image＞ ＜Knowledge, know-how, and intelligence＞ Expanding the value proposition • Expertise in highly efficient logis
Slide 20: Main initiatives to date
PALTAC Business Main initiatives to date Data-related initiatives Logistics-related initiatives A new company, “Product Registry Services , Inc.” has been Construction of a new logistics center, "RDC Kaizuka (tentative jointly established by three companies to centrally manage name)," has been decid
Slide 21: Initiatives for the Growth Strategies: MP AGRO
AGRO ＆ FOOD Business Initiatives for the Growth Strategies MP AGRO 【Expansion of AGRO&FOOD business】 Maximizing strategic synergies between MP AGRO and Cygni to drive the rapid expansion of the companion animal-related products By combining MP AGRO's cultivated "face-to- face proposal capabilities"
Slide 22: Initiatives for the Growth Strategies: MP Gokyo Food & Chemical
AGRO ＆ FOOD Business Initiatives for the Growth Strategies MP Gokyo Food & Chemical 【Expansion of AGRO&FOOD business】 Maximizing synergies from the integration of MEDIPAL FOODS and MP Gokyo Food & Chemical to accelerate the expansion of our food ingredients business Synergy effects from business int
Slide 23: Forecast of Consolidated Results for the FY2026 (provisional)
Forecast of Consolidated Results for the FY2026 (provisional) Targeting growth in both sales and operating profit for the full year (¥ billion) FY2025 FY2026 Result [% of Net Sales] Forecast [% of Net Sales] % of Change Net Sales 3,817.3 ー 3,944.0 ー +3.3% Gross Profit 260.9 [6.84%] 269.5 [6.83%] +3.
Slide 24: Contents
Contents 1 Financial Results for the FY2025 2 Major Initiatives and Outlook for the FY2026 3 Capital Policy and Shareholder Returns Copyright © 2026 MEDIPAL HOLDINGS CORPORATION, All rights reserved. 24
Slide 25: Capital Policy and Shareholder Returns
Capital Policy and Shareholder Returns Optimizing capital allocation by driving growth investments to boost corporate value, reinforcing distribution infrastructure, and maintaining a commitment to consistent shareholder returns Dividend increases for 14 consecutive Dividends （¥） periods since FY2
Slide 26: The MEDIPAL Group is accelerating its transformation to the next stage
- Constant Innovation - The MEDIPAL Group is accelerating its transformation to the next stage
Slide 27: Appendix
Appendix Copyright © 2025 MEDIPAL HOLDINGS CORPORATION, All rights reserved. 27
Slide 28: FY2025 Consolidated Statements
FY2025 Consolidated Statements (¥ billion) FY2024 FY2025 Results Forecast Results YoY Forecast Difference from （% of Net Sales） （% of Net Sales） （% of Net Sales） YoY Change % of Change % of Difference forecast Net Sales 3,671.3 3,785.0 3,817.3 +146.0 +4.0% +32.3 +0.9% Gross Profit 255.7 263.5 260.9
Slide 29: FY2025 MEDICEO Business
FY2025 MEDICEO Business (¥ billion) FY2024 FY2025 Results Results YoY （% of Net Sales) （% of Net Sales） YoY change % of Change Net Sales 2,370.2 2,４６６.１ +９５.８ +4.0% Gross Profit 150.3 15２.3 +1.9 +1.3% [6.34%] [6.１８%] [(0.17pp)] SG&A Expenses 125.1 12８.０ ＋２.８ ＋2.３% [5.28%] [5.１９%] [(0.０９pp)] SG&A Exp
Slide 30: FY2025 PALTAC Business
FY2025 PALTAC Business (¥ billion) FY2024 FY2025 Results Results YoY （% of Net Sales） （% of Net Sales） YoY Change % of Change Net Sales 1,188.0 1,２３７.８ +４９.７ +４.２% Gross 88.9 ９２.３ +３.３ +3.８% Profit [7.49%] [7.4６%] [(0.0３pp)] SG&A 60.9 6５.８ +４.９ +８.１% Expenses [5.13%] [5.３２%] [＋0.19pp] Operating 28.0
Slide 31: FY2025 AGRO・FOOD Business
FY2025 AGRO・FOOD Business (¥ billion) FY2024 FY2025 Results Results YoY （% of Net Sales) （% of Net Sales) YoY change % of Change Net Sales 116.8 11７.３ +０.４ +０.４％ Gross Profit 16.4 16.３ （０） （０.５%） [14.07%] [1３.95%] [(0.12pp)] SG&A Expenses 14.0 14.0 0 +０.３% [11.98%] [11.97%] [（0.０1pp）] SG&A Expenses
Slide 32: FY2025 Results by Segment [Compared to forecast]
FY2025 Results by Segment [Compared to forecast] MEDICEO Business PALTAC Business AGRO ＆ FOOD Business (¥ billion) Forecast Results Difference Forecast Results Difference Forecast Results Difference % of % of % of （% of Net （% of Net from （% of Net （% of Net from （% of Net （% of Net from Difference
Slide 33: Factors behind YoY changes in Gross Profit, Operating Profit and Ordinary Profit
Factors behind YoY changes in Gross Profit, Operating Profit and Ordinary Profit SG＆A expenses（Increase） Non-Operating Income/Expenses (¥ billion) +1.9 Profit from (７.６) (12.8) MEDICEO ＋3.3 Profit from ＋10.4 PALTAC profit of entities accounted for Business using equity others Investment costs method
Slide 34: Factors behind YoY changes in Ordinary Profit and Profit attributable to Owners of Parent
Factors behind YoY changes in Ordinary Profit and Profit attributable to Owners of Parent Extraordinary Income/Expenses (¥ billion) (5.3) Gain on sale of investment Amortization securities of goodwill +9.3 (9.5) Business restructuring expenses related to logistics operations※ +１０.４ (4.5) Income Prof
Slide 35: Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows (¥ billion) ＋46.5 ＋9.2 (29.3) 286.5 259.3 Cash Flows from Investing Activities Cash Flows from Financing Activities Cash Flows from • Proceeds from sale and redemption Operating Activities of investment securities：＋27.9 • Purchase of shares of subsidiaries • Pur
Slide 36: Management Philosophy
Management Philosophy Contributing to people’s health and the advancement of society through creation of value in distribution Copyright © 2026 MEDIPAL HOLDINGS CORPORATION, All rights reserved. 36
Slide 37: Forward-Looking Statements
【Forward-Looking Statements】 These materials reflect analysis of available information and various trends as of the date on the cover. Risks and uncertainties affecting the Company’s business could cause actual results to differ materially from any projections presented in these materials. In the ev